In a declaration, Zydus Cadila said that the initial phase of the H1N1 vaccine trial has been completed.

Now, the company will start the phase II and phase III clinical examinations in Bangalore, Ahmedabad, Pune and Jaipur.

The Ahmedabad-based drug manufacturer said that the next two examinations will take six months for the completion.

The company said, "Multi-centric trials extending for a period of six weeks are currently underway. On successful completion of the trials, the group will submit the results to the Drug Controller General of India (DGCI) for marketing approval."

Zydus anticipates making H1N1 vaccine available in the market by the coming month (April 2010).

Previously, the company had planned to produce six million doses in the beginning. The demand for H1N1 vaccine in the country is likely around 50 to 60 million dosages at first.

The vaccine has been formulated by a group of experts utilizing conventional technology at the company's Vaccine Technology Centre.

In India, vaccinations against the lethal swine flu virus are expected to start by the coming week.

The 1.5 million dosages of vaccines imported by the administration from Sanofi Pasteur recently, have cleared the trial.

The French vaccine makers forwarded the outcomes of their clinical bridge research carried out in the National Capital and Pune on 100 adult subjects.

The tests were completed on February 21.